<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04306913</url>
  </required_header>
  <id_info>
    <org_study_id>D-47-2019</org_study_id>
    <nct_id>NCT04306913</nct_id>
  </id_info>
  <brief_title>Outcome of Esmolol Potassium Cardioplegia Compared to Potassium Cardioplegia in Patients With Solitary Valvular Disease; Randomized Controlled Study</brief_title>
  <official_title>Outcome of Esmolol Potassium Cardioplegia Compared to Potassium Cardioplegia in Patients With Solitary Valvular Disease; Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kasr El Aini Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kasr El Aini Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Perioperative myocardial injury remains one of the most serious complications of cardiac
      surgery.

      Numerous factors have been implicated during the pathogenesis process, including the
      technique of cardiac surgery, induction of cardioplegia and period of cardiac arrest.

      Lactic acid is the normal endpoint of the anaerobic breakdown of glucose in the tissues. The
      lactate exits the cells and is transported to the liver, thus it's considered to be an
      indicator of ischemia as it is produced by most tissues in the human body, with the highest
      level of production found in muscle.

      In any cardiac valve replacement surgery, patient must undergo cardiac bypass and arrest in
      diastole by using hyperkalemic cardioplegia solution; meanwhile the metabolism of myocardial
      cells is purely anaerobic.

      Esmolol an ultra-short beta blocker is supposed to decrease the anaerobic insult to the
      myocardial cells.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Coronary sinus lactate level immediately before declamping the aorta.</measure>
    <time_frame>1 hour during declamping</time_frame>
    <description>the lactate from the coronary sinus</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Cardioplegia Solution Adverse Reaction</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Esmolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esmolol</intervention_name>
    <description>esmolol 250 mg in cardioplegia solution every 25 minutes</description>
    <arm_group_label>Esmolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Potassium Cardioplegic Solution</intervention_name>
    <description>15 meq potassium added to cardioplegia solution</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Esmolol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - 20-50 years old patients, with either sex with solitary valvular disease

        Exclusion Criteria:

          -  • Myocardial infarction within 2 weeks.

               -  History of reaction or toxicity to esmolol or other beta blockers.

               -  New York Heart Association class IV congestive heart failure despite treatment.

               -  Persistent hypotension (systolic blood pressure &lt;80 mm Hg).

               -  severe pulmonary hypertension

               -  Ejection fraction less than 45%

               -  Patients with coronary artery disease

               -  Patients with congenital heart disease

               -  Patients with previous cardiac surgery

               -  Patients with liver disease (child class B and C)

               -  Patients with second or third degree heart block

               -  Patients having resting heart rate less than 50 ppm

               -  Patients using calcium channel blockers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ayman Abougabal, PHD</last_name>
    <phone>00201020671408</phone>
    <email>ayman.abouagabal@kasralainy.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kasr alainy medical school</name>
      <address>
        <city>Cairo</city>
        <zip>12566</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <contact>
      <last_name>Noha sameh</last_name>
      <phone>01224498481</phone>
      <email>drnohnoh91@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Scorsin M, Mebazaa A, Al Attar N, Medini B, Callebert J, Raffoul R, Ramadan R, Maillet JM, Ruffenach A, Simoneau F, Nataf P, Payen D, Lessana A. Efficacy of esmolol as a myocardial protective agent during continuous retrograde blood cardioplegia. J Thorac Cardiovasc Surg. 2003 May;125(5):1022-9.</citation>
    <PMID>12771874</PMID>
  </reference>
  <reference>
    <citation>Murtuza B, Pepper JR, Stanbridge RD, Darzi A, Athanasiou T. Does minimal-access aortic valve replacement reduce the incidence of postoperative atrial fibrillation? Tex Heart Inst J. 2008;35(4):428-38. Review.</citation>
    <PMID>19156237</PMID>
  </reference>
  <reference>
    <citation>Kuhn-Régnier F, Natour E, Dhein S, Dapunt O, Geissler HJ, LaRosé K, Görg C, Mehlhorn U. Beta-blockade versus Buckberg blood-cardioplegia in coronary bypass operation. Eur J Cardiothorac Surg. 1999 Jan;15(1):67-74.</citation>
    <PMID>10077376</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 2, 2020</study_first_submitted>
  <study_first_submitted_qc>March 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2020</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kasr El Aini Hospital</investigator_affiliation>
    <investigator_full_name>Ayman Abougabal</investigator_full_name>
    <investigator_title>Consultant</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardioplegic Solutions</mesh_term>
    <mesh_term>Esmolol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

